United States of America et al v. Astrazeneca Biopharmaceuticals, Inc. et al

  1. May 15, 2017

    26 States Rejoin FCA AstraZeneca Suit Over Seroquel

    A New York federal judge on Monday reinstated the False Claims Act claims of 26 states, Washington, D.C., and the city of Chicago in a whistleblower suit accusing AstraZeneca PLC of hiding safety information about antipsychotic drug Seroquel, after the whistleblower acknowledged that she had no authority to voluntarily drop their claims.

  2. April 18, 2017

    AstraZeneca Can't Shed FCA Suit Over Seroquel 'Scheme'

    A New York federal judge on Monday preserved a whistleblower’s False Claims Act suit accusing AstraZeneca PLC of concealing safety information about antipsychotic drug Seroquel, finding plausible allegations of a “complex fraudulent scheme.”

  3. August 26, 2016

    FCA Attys Clash Over Escobar Test For Implicit Compliance

    False Claims Act attorneys are deeply split over a crucial section in the U.S. Supreme Court's Escobar ruling, debating whether its test of implicit statements about regulatory compliance is mandatory and how the test should be applied.

  4. August 15, 2016

    DOJ, Defense Attys Brawl Over Escobar's FCA Impact

    The U.S. Department of Justice and defense attorneys are sharply divided over the U.S. Supreme Court's recent Escobar decision, debating whether it limited False Claims Act liability to situations where the government would have denied payment had it known about misconduct.